Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.

Ban S, Ueda Y, Ohashi M, Matsuno K, Ikeda M, Kato N, Miyachi H.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4774-8. doi: 10.1016/j.bmcl.2013.07.005. Epub 2013 Jul 13.

PMID:
23891183
2.

Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA.

Ali Ashfaq U, Ansar M, Sarwar MT, Javed T, Rehman S, Riazuddin S.

Virol J. 2011 Mar 10;8:112. doi: 10.1186/1743-422X-8-112.

4.

Multiple effects of Honokiol on the life cycle of hepatitis C virus.

Lan KH, Wang YW, Lee WP, Lan KL, Tseng SH, Hung LR, Yen SH, Lin HC, Lee SD.

Liver Int. 2012 Jul;32(6):989-97. doi: 10.1111/j.1478-3231.2011.02621.x. Epub 2011 Aug 11.

PMID:
22098176
5.

A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication.

Fusco DN, Brisac C, John SP, Huang YW, Chin CR, Xie T, Zhao H, Jilg N, Zhang L, Chevaliez S, Wambua D, Lin W, Peng L, Chung RT, Brass AL.

Gastroenterology. 2013 Jun;144(7):1438-49, 1449.e1-9. doi: 10.1053/j.gastro.2013.02.026. Epub 2013 Feb 24.

6.

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.

Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM.

Hepatology. 2003 Oct;38(4):869-78.

PMID:
14512874
7.

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.

Zhu H, Butera M, Nelson DR, Liu C.

Virol J. 2005 Sep 7;2:80.

8.

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Huang P, Goff DA, Huang Q, Martinez A, Xu X, Crowder S, Issakani SD, Anderson E, Sheng N, Achacoso P, Yen A, Kinsella T, Darwish IS, Kolluri R, Hong H, Qu K, Stauffer E, Goldstein E, Singh R, Payan DG, Lu HH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. doi: 10.1128/AAC.00525-07. Epub 2008 Jan 28.

9.

Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome.

Trejo-Avila L, Elizondo-González R, Trujillo-Murillo Kdel C, Zapata-Benavides P, Rodríguez-Padilla C, Rivas-Estilla AM.

Ann Hepatol. 2007 Jul-Sep;6(3):174-80.

PMID:
17786145
10.

Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.

Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB.

Antimicrob Agents Chemother. 2009 Mar;53(3):926-34. doi: 10.1128/AAC.01032-08. Epub 2008 Dec 15.

11.

Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.

Liu WL, Yang HC, Su WC, Wang CC, Chen HL, Wang HY, Huang WH, Chen DS, Lai MY.

PLoS One. 2012;7(9):e43824. doi: 10.1371/journal.pone.0043824. Epub 2012 Sep 4.

12.

Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.

Matsuno K, Ueda Y, Fukuda M, Onoda K, Waki M, Ikeda M, Kato N, Miyachi H.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4276-80. doi: 10.1016/j.bmcl.2014.07.019. Epub 2014 Jul 15.

PMID:
25086684
13.
14.

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.

El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H.

Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

15.

[Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].

Kasuga J, Oyama T, Nakagome I, Aoyama A, Sako K, Makishima M, Hirono S, Morikawa K, Hashimoto Y, Miyachi H.

Yakugaku Zasshi. 2009 Jun;129(6):709-18. Review. Japanese.

16.

Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.

Sellitto G, Faruolo A, de Caprariis P, Altamura S, Paonessa G, Ciliberto G.

Bioorg Med Chem. 2010 Aug 15;18(16):6143-8. doi: 10.1016/j.bmc.2010.06.058. Epub 2010 Jun 22.

PMID:
20638289
17.

Design and synthesis of novel carbocyclic versions of 2'-spirocyclopropyl ribonucleosides as potent anti-HCV agents.

Oh CH, Kim E, Hong JH.

Nucleosides Nucleotides Nucleic Acids. 2011 Jun;30(6):423-39. doi: 10.1080/15257770.2011.587490.

PMID:
21780908
18.

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT.

J Virol. 2002 Sep;76(17):8505-17.

19.

A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.

Katsume A, Tokunaga Y, Hirata Y, Munakata T, Saito M, Hayashi H, Okamoto K, Ohmori Y, Kusanagi I, Fujiwara S, Tsukuda T, Aoki Y, Klumpp K, Tsukiyama-Kohara K, El-Gohary A, Sudoh M, Kohara M.

Gastroenterology. 2013 Oct;145(4):865-73. doi: 10.1053/j.gastro.2013.06.012. Epub 2013 Jun 18.

20.

Hepatitis C virus genetic variability in patients undergoing antiviral therapy.

Cristina J, del Pilar Moreno M, Moratorio G.

Virus Res. 2007 Aug;127(2):185-94. Epub 2007 Apr 20. Review.

PMID:
17449128

Supplemental Content

Support Center